Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas.

about

Aldoxorubicin: a tumor-targeted doxorubicin conjugate for relapsed or refractory soft tissue sarcomas.

Item

http://www.wikidata.org/entity/Q55092685

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Aldoxorubicin: a tumor-targete ...... fractory soft tissue sarcomas.

@en

Aldoxorubicin: a tumor-targete ...... fractory soft tissue sarcomas.

@nl

type

Item

label

Aldoxorubicin: a tumor-targete ...... fractory soft tissue sarcomas.

@en

Aldoxorubicin: a tumor-targete ...... fractory soft tissue sarcomas.

@nl

prefLabel

Aldoxorubicin: a tumor-targete ...... fractory soft tissue sarcomas.

@en

Aldoxorubicin: a tumor-targete ...... fractory soft tissue sarcomas.

@nl

P1476

Aldoxorubicin: a tumor-targete ...... fractory soft tissue sarcomas.

@en

P2093

Andrew Hendifar

http://www.w3.org/2001/XMLSchema#string

Charles Forscher

http://www.w3.org/2001/XMLSchema#string

Jessica Yan

http://www.w3.org/2001/XMLSchema#string

Jun Gong

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.

Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care.

Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor.

Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review.

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.

Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

P304

777-786

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.2147/DDDT.S140638

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2018-04-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29670334

http://www.w3.org/2001/XMLSchema#string

P921

P932

5896668

http://www.w3.org/2001/XMLSchema#string